Journal article

Tumor Necrosis Factor Gene Variation Predicts Hippocampus Volume in Healthy Individuals

Bernhard T Baune, Carsten Konrad, Dominik Grotegerd, Thomas Suslow, Patricia Ohrmann, Jochen Bauer, Volker Arolt, Walter Heindel, Katharina Domschke, Sonja Schoening, Astrid Veronika Rauch, Christina Sehlmeyer, Harald Kugel, Udo Dannlowski

Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2012

University of Melbourne Researchers

Grants

Awarded by Innovative Medizinische Forschung of the Medical Faculty of Munster


Awarded by Rolf-Dierichs-Stiftung


Funding Acknowledgements

The study was supported by grants from Innovative Medizinische Forschung of the Medical Faculty of Munster (DA120309, DA111107, and DA211012 to UD), Rolf-Dierichs-Stiftung (ZUW80037 to UD), and Interdisziplinares Zentrum fur Klinische Forschung of the Medical Faculty of Munster.Professor Volker Arolt, M. D., Ph.D., is a member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pfizer, and Wyeth. He chairs the committee for the "Wyeth Research Award Depression and Anxiety," now the DGPPN/Pfizer "Clinical Neuroscience Award." Professor Bernhard T. Baune, M. D., P. h. D., M. P. H., is a member of advisory boards and/or gave presentations for the following companies: AstraZeneca, Lundbeck, Pfizer, Servier, and Wyeth. He receives funding from the National Health and Medical Research Council Australia. Professor Katharina Domschke, M. A., M. D., Ph.D., is on the speakers' board of Pfizer, Lilly, and Bristol-Myers Squibb; has been a consultant for Johnson and Johnson, and has received funding by Astra Zeneca. These affiliations have no relevance to the work covered in the manuscript. All other authors report no biomedical financial interests or potential conflicts of interest.